EX-99.1 2 drr0162_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

  Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN: L85195TG1984PLC004507
 
Tel      :+91 40 4900 2900
Fax     :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com

 

October 5, 2019

 

Corporate Relationship Department   National Stock Exchange of India Ltd.
BSE Limited   “Exchange Plaza”
Dalal Street, Fort   Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001   Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /   Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039   26598238

 

Scrip Code: 500124 Scrip Code: DRREDDY-EQ

 

Dear Sirs,

Sub: Intimation

 

Further to our intimation dated July 12, 2019 with regard to the audit of our API manufacturing plant 2 at Bollaram, Hyderabad, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated (VAI).

 

This is for your information.

 

With regards,

 

/s/ Sandeep Poddar  
Sandeep Poddar  
Company Secretary  

  

CC:- New York Stock Exchange Inc.(Stock Code :RDY)